Stock Analyst Downgrades → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Reporting Date Country USA (NYSE & NASDAQ) United States(NYSE & NASDAQ) United States(All Exchanges) Canada United Kingdom Sector All Sectors Aerospace Auto/Tires/Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Goods Consumer Staples Finance Industrial Products Medical Miscellaneous Multi-Sector Conglomerates Oils/Energy Retail/Wholesale Services Transportation Utilities All Market Caps Large Cap ($10B+) Medium Cap ($2B-$10B) Small Cap (<$2B) Market Cap All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action All Ratings Strong Buy Buy Hold Sell Rating Export to Excel CompanyActionBrokerageAnalystCurrent PricePrice TargetRatingDetailsABNBAirbnb Downgraded byHSBCSubscribe to MarketBeat All Access for the recommendation accuracy rating$147.05-6.9%$160.00 ➝ $156.00Buy ➝ HoldDVDoubleVerify Downgraded byBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy rating$18.84+0.3%$45.00 ➝ $18.00Buy ➝ UnderperformEHABEnhabit Downgraded byJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating$8.29-14.5%$14.00 ➝ $8.75Buy ➝ HoldSEDGSolarEdge Technologies Downgraded byNorthland SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy rating$52.67-8.5%Outperform ➝ Market PerformSWKSSkyworks Solutions Downgraded byWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy rating$92.25-1.1%Outperform ➝ Peer PerformTRIPTripadvisor Downgraded byDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy rating$18.31+0.8%$31.00 ➝ $20.00Buy ➝ Neutral Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. VRDNViridian Therapeutics Downgraded byB. RileySubscribe to MarketBeat All Access for the recommendation accuracy rating$13.91-6.6%$25.00 ➝ $20.00Buy ➝ NeutralVRDNViridian Therapeutics Downgraded byLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy rating$13.91-6.6%Buy ➝ NeutralAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:10 AM ET. Stock Ratings Reports and Tools Today's Ratings: U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top Rated Stocks: Top Rated Stocks Top Rated Dividend Stocks Top Rated Small-Cap Stocks Top Rated Tech Stocks Most Upgraded Stocks Most Downgraded Stocks Lowest Rated Stocks More Ratings Tools: Stock Ratings by Company Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Ratings for Popular Stocks: Alphabet (Google) Amazon Apple Meta (Facebook) Microsoft Netflix Nvidia Tesla Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
